Wilmer Cutler Pickering Hale and Dorr represented Siolta Therapeutics, Inc. in the transaction. Siolta Therapeutics, Inc. announced it has raised $12 million in Series C Preferred...
Siolta Therapeutics’ $12 Million Series C Financing Round
BiomX’s Merger with Adaptive Phage Therapeutics
Haynes and Boone is advising BiomX Inc. on the transaction, Cooley is advising Adaptive Phage Therapeutics and Wilmer Cutler Pickering Hale and Dorr is advising the...
Astria Therapeutics’ $125 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Astria Therapeutics, Inc., and Cooley advised the underwriters. Astria Therapeutics, Inc. (Astria) (Nasdaq: ATXS) announced it completed its underwritten registered...
State Street Corporation’s $1.5 Billion Depositary Shares Offering
Wilmer Cutler Pickering Hale and Dorr advised State Street Corporation on the offering, and Cravath, Swaine & Moore advised the underwriters. State Street Corporation (“State Street”)...
TechTarget’s Combination with Informa
Wilmer Cutler Pickering Hale and Dorr represented TechTarget, Inc. in the transaction, and Clifford Chance represented Informa PLC. TechTarget, Inc. (NASDAQ: TTGT) and Informa PLC (LSE:...
Dyne Therapeutics’ $345 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc., and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) (“Dyne”) announced the closing of an underwritten public offering...
Solid Biosciences’ $109 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr advised Solid Biosciences Inc. on the deal. Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines...
Voyager Therapeutics’ $100 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced an underwritten public offering...
Kymera Therapeutics’ $316.2 Million Common Stock Offering
Goodwin Procter advised Kymera Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (“Kymera”) announced its...
Arbor Biotechnologies’ Partnership with 4D Molecular Therapeutics
Wilmer Cutler Pickering Hale and Dorr represented Arbor Biotechnologies in the transaction. Arbor Biotechnologies announced a strategic partnership with 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT). As part of...
Voyager Therapeutics’ Capsid License Agreement and Strategic Collaboration with Novartis
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
Air Space Intelligence’s$34 Million Series B Financing Round
Wilmer Cutler Pickering Hale and Dorr represented Air Space Intelligence in the transaction. Air Space Intelligence (ASI) announced the completion of a $34 million Series B funding round....